

Umifenovir + Hydroxychloroquine vs Lopinavir Ritonavir + Hydroxychloroquine for COVID-19

Author(s): Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M.

Question: Should Umifenovir + Hydroxychloroquine compared to Lopinavir / Ritonavir + Hydroxychloroquine be used for COVID-19?

Setting: Inpatient

Certainty assessment							№ of patients		Effect		Certainty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Umifenovir + Hydroxychloroquine	Lopinavir / Ritonavir + Hydroxychloroquine	Relative (95% CI)	Absolute (95% CI)	
All-cause mortality at 30 days											
1 ¹	randomised trials	serious ^a	not serious	not serious	serious ^b	none	1/50 (2.0%)	2/50 (4.0%)	RR 0.50 (0.05 to 5.34)	20 fewer per 1.000 (from 38 fewer to 174 more)	⊕⊕○○ LOW
Length of stay in hospital											
1 ¹	randomised trials	serious ^a	not serious	not serious	serious ^b	none	50	50	-	SMD 0.48 lower (0.88 lower to 0.08 lower)	⊕⊕○○ LOW
Number of patients with adverse events											
1 ¹	randomised trials	serious ^a	not serious	not serious	serious ^b	none	3/50 (6.0%)	12/50 (24.0%)	RR 0.25 (0.08 to 0.83)	180 fewer per 1.000 (from 221 fewer to 41 fewer)	⊕⊕○○ LOW

Explanations

a. Downgraded of one level for high risk of performance bias and unclear risk of reporting bias

b. Downgraded of one level for small sample size

References

1. Nojomi M, Yasin Z, Keyvani H, Makiani MJ, Roham M, Laali A et al. Effect of Arbidol on COVID-19: A Randomized Controlled Trial. Research Square; 2020.